Nick Paul Taylor

Biography for Nick Paul Taylor

Nick Taylor, UK Correspondent

Nick Taylor is a freelance journalist with more than six years' experience of reporting on the global biopharma industry. Since graduating with a biology degree from the University of York, Nick has written for numerous healthcare publications, including Nature BioPharma Dealmakers, Life Science Leader and Outsourcing-Pharma. You can contact him at ntaylor@fiercemarkets.com and follow him on Twitter at @NickPaulTaylor.

Articles by Nick Paul Taylor

Regeneron allies with DNAnexus on 100,000 exomes project

Faced with the challenge of how to handle data from the 100,000 exomes it intends to sequence, Regeneron has struck a deal with DNAnexus to access cloud-based infrastructure.The biotech is working with DNAnexus through the Regeneron Genetics Center it established for the sequencing project.

BBK inks deal to buy mobile app development unit

The acquisition tightens BBK's ties to the team that helped to develop its patient and site engagement mobile app, My Clinical Study Buddy.

Genomics England picks 10 firms for next round of bioinformatics talent contest

Genomics England has dropped two-thirds of the candidates to provide variant annotation and clinical interpretation services to the 100,000 Genomes Project after reviewing the first round of responses.

Researchers join forces to build database of 50M genetic variants

The genetic research community is about to get access to a lot of data. On October 20, two public databases generated by whole-genome and exome sequencing at multiple research institutions will be unveiled.

Report: Novo Nordisk to file for IT unit IPO in coming days

Novo Nordisk is reportedly set to unveil details of an IPO of its IT services business NNIT in the coming days. The Danish drugmaker has spent most of 2014 assessing whether to spin off the unit as an independent company.

EMA to discuss possible glitch in Thermo bioequivalence software

Increased reliance on software to support aspects of drug development has simplified many tasks but created the possibility that an IT glitch could have far-reaching implications. Now, the European Medicines Agency is to discuss whether this situation has already happened.

NIH turns on Big Data funding faucet

The National Institutes of Health has kicked off its Big Data to Knowledge (BD2K) initiative with an initial $32 million in funding. Harvard, Stanford and other universities received some of the cash to set up Centers of Excellence for Big Data Computing, each of which will tackle a different aspect of turning numbers into biomedical understanding.

ISB teams with Google for NCI Cancer Genomics Cloud project

The list of life science data projects underpinned by Google keeps getting longer. Having signed up to the BRAIN Initiative last week, Google has now teamed up with ISB and SRA International to work on a project for the National Cancer Institute.

Merck's VC unit invests in data security business

With report after report finding flaws in the data security practices of healthcare and life science organizations, Exostar has decided to accelerate its expansion into the sector. And the company has snagged funding from the Merck Global Health Innovation Fund to support its plans.

Merck and Pfizer join Accenture's Life Sciences Cloud Coalition

Accenture has joined with some big names for its R&D analytics platform. Eisai, Merck and Pfizer have signed up to collaborate on further development of the system, which is built on a mix of technologies from Accenture and Oracle.